Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% - Here's What Happened

Key Points

• Taysha Gene Therapies shares rose 5.7% to about $4.94, despite trading volume running 41% below the average session level.
• Analysts remain broadly bullish, with a consensus “Buy” rating and an average price target of $12.77; recent targets range from $10 to $14.
• The company reported a quarterly loss of $0.13 per share, missing estimates by $0.02, while an insider sold 200,000 shares under a pre-arranged trading plan.

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) traded up 5.7% during trading on Monday. The company traded as high as $4.91 and last traded at $4.9360. Approximately 1,725,473 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 2,924,317 shares. The stock had previously closed at $4.67.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TSHA. Bank of America raised their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday, June 22nd. Citizens Jmp restated a "market outperform" rating and issued a $11.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, July 2nd. BMO Capital Markets lifted their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an "outperform" rating in a report on Tuesday, June 23rd. Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research report on Tuesday, June 23rd. Finally, The Goldman Sachs Group raised their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $12.77.

Taysha Gene Therapies Stock Performance

The business's 50-day simple moving average is $5.70 and its two-hundred day simple moving average is $5.68. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -12.00 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). As a group, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction on Friday, July 10th. The shares were sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the completion of the transaction, the insider directly owned 936,410 shares in the company, valued at approximately $5,843,198.40. This represents a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.48% of the company's stock.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors and hedge funds have recently modified their holdings of TSHA. R Squared Ltd acquired a new stake in Taysha Gene Therapies in the 1st quarter valued at about $50,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Taysha Gene Therapies in the first quarter valued at approximately $51,000. Principal Financial Group Inc. increased its holdings in shares of Taysha Gene Therapies by 26.2% in the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company's stock valued at $72,000 after purchasing an additional 3,362 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Taysha Gene Therapies by 698.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,577 shares of the company's stock worth $141,000 after buying an additional 22,373 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in Taysha Gene Therapies by 34.5% during the first quarter. Cetera Investment Advisers now owns 28,450 shares of the company's stock worth $127,000 after buying an additional 7,296 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company developing gene therapies for severe monogenic diseases of the central nervous system. The company focuses on disorders in which a missing or defective gene contributes to neurological disease and uses adeno-associated virus (AAV) vectors to deliver functional genetic material to targeted cells.

Taysha's development programs have included TSHA-102, an investigational gene therapy for Rett syndrome, and earlier programs such as TSHA-120 for giant axonal neuropathy and TSHA-101 for GM1 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.